Document is current
Any future updates will be listed below
-
Authors
Orellana, Minerva https://orcid.org/0000-0002-0152-7117
Riggan, Kirsten A. https://orcid.org/0000-0002-0127-9555
DSouza, Karen https://orcid.org/0000-0003-3230-5100
Stewart, Elizabeth A. https://orcid.org/0000-0003-1110-2400
Venable, Sateria
Balls-Berry, Joyce E. https://orcid.org/0000-0003-3497-1115
Allyse, Megan A. https://orcid.org/0000-0001-6136-9256
-
Funding
Funding for this research was provided by:
National Center for Advancing Translational Sciences (TL1 TR002380)
Mayo Clinic Office for Health Disparities
- License Information
-
More Information
Article History
Received: 18 January 2021
Revised: 11 May 2021
Accepted: 12 May 2021
First Online: 19 May 2021
Declarations
:
: The Mayo Clinic Institutional Review Board has approved this study Going FAR: Uterine Fibroids and Reproduction under IRB#: 17-010494.
: We obtained written informed consent from participants in this study.
: We have obtained HIPAA authorization from participants and de-identified participant information in this study.
: The authors MO, KR, KD, and MA report no conflicts of interest. EAS, JBB, and SV report additional funding from the Agency for Healthcare Research and Quality grant P50HS023418. JBB reports consultation with Boston Scientific and Parabon NanoLabs, Inc. EAS reports consulting for AbbVie, Bayer, ObsEva, and Myovant related to uterine fibroids and payment for development of educational content from UpToDate, Med Learning Group, PER, and Peer View. SV reports consulting for AbbVie, Myovant, Bayer.
: Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
